If OpenAI goes down, the cascading effect could be devastating, Ed Zitron wrote recently.

Merck's LIPFENDRA (enlicitide), the first FDA-approved oral PCSK9 inhibitor, approved 16 July 2026 at a list price of $315 for a 30-day supply. Amgen's Repatha (evolocumab) is already available for ...